Whole genome sequencing for M/XDR tuberculosis surveillance and for resistance testing

Clinical Microbiology and Infection

Volumn 23, Issue 3, 2017, Pages 161-166

  Walker, T M ^a   Merker, M ^b   Kohl, T A ^b   Crook, D W ^a,c   Niemann, S ^b,d   Peto, T E A ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b RESEARCH CENTER BORSTEL   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d German Center for Infection Research   (Germany)

Author keywords

Drug resistance; Extensive drug resistance; Multi drug resistance; Surveillance; Susceptibility; Tuberculosis; Whole genome sequencing

Indexed keywords

TUBERCULOSTATIC AGENT;

DISEASE RESISTANCE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE TECHNOLOGY; GENETIC SUSCEPTIBILITY; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PERSONALIZED MEDICINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS CONTROL; WHOLE GENOME SEQUENCING; WORLD HEALTH ORGANIZATION; BACTERIAL GENOME; BACTERIUM IDENTIFICATION; CLASSIFICATION; DNA SEQUENCE; DRUG EFFECTS; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR EPIDEMIOLOGY; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

BACTERIAL TYPING TECHNIQUES; GENOME, BACTERIAL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; MYCOBACTERIUM TUBERCULOSIS; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85006994024     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.10.014     Document Type: Review

References (59)

1. [1] World Health Organization. The End TB Strategy. Available at: http://who.int/tb/post2015_TBstrategy.pdf?ua=1 (accessed 3 January 2015).
2. [2] Didelot, X., Bowden, R., Wilson, D.J., Peto, T.E.A., Crook, D.W., Transforming clinical microbiology with bacterial genome sequencing. Nat Rev Genet 13 (2012), 601–612.
3. [3] Quick, J., Loman, N.J., Duraffour, S., Simpson, J.T., Severi, E., Cowley, L., et al. Real-time, portable genome sequencing for Ebola surveillance. Nature 530 (2016), 228–232.
4. [4] Walker, T.M., Kohl, T.A., Omar, S.V., Hedge, J., Del Ojo Elias, C., Bradley, P., et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 15 (2015), 1193–1202.
5. [5] Scott, L.E., McCarthy, K., Gous, N., Nduna, M., Van Rie, A., Sanne, I., et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med, 8, 2011, e1001061.
6. [6] World Health Organization, Global Tuberculosis Report., 20th ed., 2015 Available at: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1 (accessed 3 July 2016).
7. [7] World Health Organization, An Expanded DOTS Framework for Effective Tuberculosis Control. 2002, WHO, Geneva.
8. [8] National Institute for Clinical Excellence, Tuberculosis. London, 2016, 1–178 Available at: https://www.nice.org.uk/guidance/ng33/ (accessed 3 July 2016).
9. [9] Hopewell, P.C., Fair, E., Miller, C., Recommendations for Investigating Contacts of Persons with Infectious Tuberculosis in Low- and Middle-Income Countries. 2012, World Health Organization, France Available at: http://apps.who.int/iris/bitstream/10665/77741/1/9789241504492_eng.pdf (accessed 3 July 2016).
10. [10] Niemann, S., Supply, P., Diversity and evolution of Mycobacterium tuberculosis: moving to whole-genome-based approaches. Cold Spring Harbor Persp Med 4 (2014), a021188–8.
11. [11] Roetzer, A., Diel, R., Kohl, T.A., Rückert, C., Nübel, U., Blom, J., et al. Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study. PLoS Med, 10, 2013, e1001387.
12. [12] Walker, T.M., Lalor, M.K., Broda, A., Saldana Ortega, L., Morgan, M., Parker, L., et al. Assessment of Mycobacterium tuberculosis transmission in Oxfordshire, UK, 2007–12, with whole pathogen genome sequences: an observational study. Lancet Resp Med 2 (2014), 285–292.
13. [13] Guerra-Assunção, J.A., Crampin, A.C., Houben, R., Mzembe, T., Mallard, K., Coll, F., et al. Large-scale whole genome sequencing of M. tuberculosis provides insights into transmission in a high prevalence area. eLife Sci, 4, 2015, e05166.
14. [14] Chiappini, E., Sollai, S., Bonsignori, F., Galli, L., de Martino, M., Controversies in preventive therapy for children contacts of multidrug-resistant tuberculosis. J Chemother 26 (2014), 1–12.
15. [15] Pankhurst, L.J., Del Ojo Elias, C., Votintseva, A.A., Walker, T.M., Cole, K., Davies, J., et al. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study. Lancet Resp Med 4 (2016), 49–58.
16. [16] Walker, T.M., Ip, C.L., Harrell, R.H., Evans, J.T., Kapatai, G., Dedicoat, M.J., et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis 13 (2013), 137–146.
17. [17] Bryant, J.M., Schurch, A.C., van Deutekom, H., Inferring patient to patient transmission of Mycobacterium tuberculosis from whole genome sequencing data. BMC Infect Dis, 13, 2013, 110 1–12.
18. [18] Guerra-Assunção, J.A., Houben, R.M.G.J., Crampin, A.C., Mzembe, T., Mallard, K., Coll, F., et al. Recurrence due to relapse or reinfection with Mycobacterium tuberculosis: a whole-genome sequencing approach in a large, population-based cohort with a high HIV infection prevalence and active follow-up. J Infect Dis 211:7 (2015), 1154–1163.
19. [19] Kato-Maeda, M., Ho, C., Passarelli, B., Banaei, N., Grinsdale, J., Flores, L., et al. Use of whole genome sequencing to determine the microevolution of Mycobacterium tuberculosis during an outbreak. PLoS One, 8, 2013, e58235.
20. [20] Stucki, D., Ballif, M., Bodmer, T., Coscolla, M., Maurer, A.-M., Droz, S., et al. Tracking a tuberculosis outbreak over 21 years: strain-specific single-nucleotide polymorphism typing combined with targeted whole-genome sequencing. J Infect Dis 211:8 (2015), 1306–1316.
21. [21] Kohl, T.A., Diel, R., Harmsen, D., Rothgänger, J., Walter, K.M., Merker, M., et al. Whole-genome-based Mycobacterium tuberculosis surveillance: a standardized, portable, and expandable approach. J Clin Microbiol 52:7 (2014), 2479–2486.
22. [22] Luheshi L, Raza S, Moorthie S, Hall A, Blackburn L, Rands C, et al. Pathogen Genomics Into Practice PHG Foundation (2015). Cambridge.
23. [23] Eldholm, V., Norheim, G., Lippe von der, B., Kinander, W., Dahle, U.R., Caugant, D.A., et al. Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient. Genome Biol, 15, 2014, 490.
24. [24] Liu, Q., Via, L.E., Luo, T., Liang, L., Liu, X., Wu, S., et al. Within patient microevolution of Mycobacterium tuberculosis correlates with heterogeneous responses to treatment. Sci Rep, 5, 2015, 17507.
25. [25] Ford, C.B., Shah, R.R., Maeda, M.K., Gagneux, S., Murray, M.B., Cohen, T., et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 45:7 (2013), 784–790.
26. [26] Casali, N., Nikolayevskyy, V., Balabanova, Y., Harris, S.R., Ignatyeva, O., Kontsevaya, I., et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 46 (2014), 279–286.
27. [27] Merker, M., Blin, C., Mona, S., Duforet-Frebourg, N., Lecher, S., Willery, E., et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat Genet 47 (2015), 242–249.
28. [28] Ioerger, T.R., Feng, Y., Chen, X., Dobos, K.M., Victor, T.C., Streicher, E.M., et al. The non-clonality of drug resistance in Beijing-genotype isolates of Mycobacterium tuberculosis from the Western Cape of South Africa. BMC Genomics, 11, 2010, 670.
29. [29] Cohen, K.A., Abeel, T., Manson McGuire, A., Desjardins, C.A., Munsamy, V., Shea, T.P., et al. Evolution of extensively drug-resistant tuberculosis over four decades: whole genome sequencing and dating analysis of Mycobacterium tuberculosis isolates from KwaZulu-Natal. PLoS Med 12 (2015), e1001880–22.
30. [30] McGrath, M., Gey van Pittius, N.C., van Helden, P.D., Warren, R.M., Warner, D.F., Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 69 (2014), 292–302.
31. [31] Sergeev, R., Colijn, C., Murray, M., Cohen, T., Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis. Science Translational Medicine, 4, 2012, 135ra67.
32. [32] Strauss, O.J., Warren, R.M., Jordaan, A., Streicher, E.M., Hanekom, M., Falmer, A.A., et al. Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. J Clin Microbiol 46 (2008), 1514–1516.
33. [33] Eldholm, V., Rieux, A., Monteserin, J., Montana Lopez, J., Palmero, D., Lopez, B., et al. Impact of HIV co-infection on the evolution and transmission of multidrug- resistant tuberculosis. ELife, 5, 2016: Aug 9 pii: e16644.
34. [34] Lanzas, F., Karakousis, P.C., Sacchettini, J.C., Ioerger, T.R., Multidrug-resistant tuberculosis in panama is driven by clonal expansion of a multidrug-resistant Mycobacterium tuberculosis strain related to the KZN extensively drug-resistant M. tuberculosis strain from South Africa. J Clin Microbiol 51 (2013), 3277–3285.
35. [35] World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF System. Geneva: World Health Organization; 2011:1–36.
36. [36] Global team aim faster, more effective TB diagnosis. OxAcUk. Available at: http://www.ox.ac.uk/news/2016-03-24-global-team-aim-faster-more-effective-tb-diagnosis (accessed 3 July 2016).
37. [37] Miotto, P., Cabibbe, A.M., Feuerriegel, S., Casali, N., Drobniewski, F., Rodionova, Y., et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. Mbio 5:5 (2014 Oct 21), e01819–14.
38. [38] World Health Organization, World, The shorter MDR-TB regimen. 2016, 1–2 Available at: http://www.who.int/tb/Short_MDR_regimen_factsheet.pdf (accessed 3 July 2016).
39. [39] Jamieson, F.B., Guthrie, J.L., Neemuchwala, A., Lastovetska, O., Melano, R.G., Mehaffy, C., Profiling of rpoB Mutations and MICs for Rifampin and Rifabutin in Mycobacterium tuberculosis. J Clin Microbiol 52:6 (2014), 2157–2162.
40. [40] Farhat, M.R., Sultana, R., Iartchouk, O., Bozeman, S., Galagan, J., Sisk, P., et al. Genetic determinants of drug resistance in Mycobacterium tuberculosis and their diagnostic value. Am J Resp Crit Care Med 194:5 (2016), 621–630.
41. [41] Earle, S.G., Wu, C.-H., Charlesworth, J., Stoesser, N., Gordon, N.C., Walker, T.M., et al. Identifying lineage effects when controlling for population structure improves power in bacterial association studies. Nature Microbiol, 1, 2016, 16041.
42. [42] McGrath, M., Gey van Pittius, N.C., Sirgel, F.A., Van Helden, P.D., Warren, R.M., Moxifloxacin retains antimycobacterial activity in the presence of gyrA mutations. Antimicrob Agents Chemother 58 (2014), 2912–2915.
43. [43] Nebenzahl-Guimaraes, H., Jacobson, K.R., Farhat, M.R., Murray, M.B., Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 69 (2014), 331–342.
44. [44] Dominguez, J., Boettger, E.C., Cirillo, D., Cobelens, F., Eisenach, K.D., Gagneux, S., et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis 20 (2016), 24–42.
45. [45] Huyen, M.N.T., Cobelens, F.G.J., Buu, T.N., Lan, N.T.N., Dung, N.H., Kremer, K., et al. Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes. Antimicrob Agents Chemother 57:8 (2013), 3620–3627.
46. [46] Stewart, S.M., Crofton, J.W., The clinical significance of low degrees of drug resistance in pulmonary tuberculosis. Am Rev Respir Dis 89 (1964), 811–829.
47. [47] Zheng, X., Zheng, R., Hu, Y., Werngren, J., Davies Forsman, L., Mansjö, M., et al. Determination of Minimum Inhibitory Concentration (MIC) Breakpoints for second-line drugs associated with clinical outcomes in multidrug-resistant tuberculosis treatment in China. Antimicrob Agents Chemother 60:8 (2016), 4786–4792.
48. [48] Böttger, E.C., The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 17 (2011), 1128–1134.
49. [49] Otchere, I.D., Asante-Poku, A., Osei-Wusu, S., Baddoo, A., Sarpong, E., Ganiyu, A.H., et al. Detection and characterization of drug-resistant conferring genes in Mycobacterium tuberculosis complex strains: a prospective study in two distant regions of Ghana. Tuberculosis 99 (2016), 147–154.
50. [50] Comas, I., Borrell, S., Roetzer, A., Rose, G., Malla, B., Kato-Maeda, M., et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 44 (2011), 106–110.
51. [51] Safi, H., Lingaraju, S., Amin, A., Kim, S., Jones, M., Holmes, M., et al. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl. Nat Genet 45 (2013), 1190–1197.
52. [52] Pantel, A., Petrella, S., Veziris, N., Matrat, S., Bouige, A., Ferrand, H., et al. Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis. J Antimicrob Chemother 71:9 (2016), 2428–2431.
53. [53] Almeida, D., Ioerger, T., Tyagi, S., Li, S.-Y., Mdluli, K., Andries, K., et al. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2016 AAC.00753–16.
54. [54] Drobniewski, F., Rusch-Gerdes, S., Hoffner, S., Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST document E.DEF 8.1)–report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Clin Microbiol Infect 13 (2007), 1144–1156.
55. [55] Bradley, P., Gordon, N.C., Walker, T.M., Dunn, L., Heys, S., Huang, B., et al. Rapid antibiotic resistance predictions from genome sequence data for S. aureus and M. tuberculosis. Nat Commun, 6, 2015 Dec 21, 10063.
56. [56] Steiner, A., Stucki, D., Coscolla, M., Borrell, S., Gagneux, S., KvarQ: targeted and direct variant calling from fastq reads of bacterial genomes. BMC Genomics, 15, 2014, 881.
57. [57] Feuerriegel, S., Schleusener, V., Beckert, P., Kohl, T.A., Miotto, P., Cirillo, D.M., et al. PhyResSE: a web tool delineating Mycobacterium tuberculosis antibiotic resistance and lineage from whole-genome sequencing data. J Clin Microbiol 53 (2015), 1908–1914.
58. [58] Witney, A.A., Gould, K.A., Arnold, A., Coleman, D., Delgado, R., Dhillon, J., et al. Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. J Clin Microbiol 53 (2015), 1473–1483.
59. [59] Churchyard, G.J., Stevens, W.S., Mametja, L.D., McCarthy, K.M., Chihota, V., Nicol, M.P., et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. The Lancet Global Health 3 (2015), e450–e457.